Teriparatide + Oral PTH (1-34)
Phase 1Completed 0 watching 0 views this week๐ค Quiet
25
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug Safety and Bioavailability
Conditions
Drug Safety and Bioavailability
Trial Timeline
Oct 1, 2013 โ Oct 1, 2017
NCT ID
NCT02571140About Teriparatide + Oral PTH (1-34)
Teriparatide + Oral PTH (1-34) is a phase 1 stage product being developed by Entera Bio for Drug Safety and Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT02571140. Target conditions include Drug Safety and Bioavailability.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02571140 | Phase 1 | Completed |
Competing Products
20 competing products in Drug Safety and Bioavailability